Navigation Links
ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
Date:2/6/2008

e devices world-wide to 166.

With respect to the Company's strategy to expand into new regenerative medicine markets, Osgood noted, "Our newest initiative in this regard is the MarrowXpress(TM), a version of our AutoXpress(TM) Platform targeted to the processing of bone marrow. Our initial focus will be in the use of bone marrow stem cells in the treatment of critical limb ischemia and myocardial ischemia. We are in the process of preparing a 510 (k) submission and CE Mark application."

Separately, the Company announced today the creation of a wholly-owned subsidiary, Vantus(TM) Inc. a veterinary stem cell laboratory services company. Its initial focus will be the harvesting, processing and preservation of equine stem cells for use in treatment of orthopedic injuries in the performance equine market. The Company is also close to completing a formal collaboration with the Center for Equine Health and Stem Cell Regenerative Medicine Group at the University of California, Davis, School of Veterinary Medicine.

"We are making meaningful progress across our entire business, as well as hitting key milestones in our regenerative medicine strategy. We remain optimistic about our long-term prospects and the value of our technology to facilitate our growth initiatives," Osgood said.

For the first six months of fiscal 2008, ThermoGenesis reported revenues of $9.1 million versus $8.0 million in the same period a year ago. Disposable revenues were $4.5 million versus $2.8 million, a 61% increase. The Company reported a net loss of $4.0 million, or $0.07 per share, in the first six months of fiscal 2008, versus a net loss of $3.1 million, or $0.06 per share, in the same period a year ago.

Consistent with prior guidance, the Company said that during the remainder of fiscal 2008, management expects to see continued sequential quarterly revenue growth through a full AXP production ramp and strong BioArchive sales. Management also expects quarterly r
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
8. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
9. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
10. Helix BioPharma Corp. announces fiscal 2007 results
11. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor of infant and children,s formul
(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Dutch Biotech Company Pepscan Appoints New CEO 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
...dium Therapeutics,(Amex: CXM ) announced positive...ed by researchers at Emory University, which demon...rs within acutely ischemic myocardium,(heart muscl...ckage of the,coronary arteries). The study employe...a heart attack or acute myocardial infarction, in ...
...ch 11 Pressure,BioSciences, Inc. (Nasdaq: PBIO )...s joined PBI,s senior executive management team as...im nearly twenty years of experience in,sales and ...ces companies.,Mr. Potter will oversee PBI,s seven...sponsible for driving the Company,s commercializat...
...11 Schering-Plough,Corporation (NYSE: SGP ) toda... Administration (FDA) of a New Drug Application (N... in the dosage strength of 20 mg of,omeprazole as ...frequent,heartburn., The NDA was submitted under ...c. of San Diego, Calif., which was signed in Octob...
Other Biology Technology:Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 2Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 3Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 4Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 5Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 6Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 7Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 2Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R) 3
(Date:12/4/2009)By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)A coating on windows or solar panels that repels grime and dirt? Expanded battery storage capacities for the next electric car? New Tel Aviv University research, just published in Nature Nanotechnolo
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2New therapy targets for amyloid disease 2A window that washes itself? 2Genomic Health to Present at Piper Jaffray Health Care Conference 14955 1Genomic Health to Present at Piper Jaffray Health Care Conference 14955 2Visage Imaging Introduces Visage 28R 29 7 for Windows and Mac OS X 6500 1Visage Imaging Introduces Visage 28R 29 7 for Windows and Mac OS X 6500 2Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 6495 1Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 6495 2
...t trimester of pregnancy is clearly linked with an...at play a role in detoxification of cigarette smok... new study published in the journal Epidemiology ... defects. Closure of the lip occurs about 5 weeks ...at week 9. If this does not happen, a cleft lip an...
...gemeinschaft (DFG, German Research Foundation) has...y innovative and higher-risk research. They are th...e DFG,s Reinhart Koselleck Projects programme. The...euros and 1.25 million euros for their planned res...y over a five-year period. , The DFG,s Reinhart ...
...gical tit for tat may hold clues to improving the ... type 1 diabetes, according to a Medical College o...em attacks insulin-producing cells causing high bl... attack, said Dr. Rafal Pacholczyk, an immunologis...Medicine. , He just received a three-year, $495,0...
Other Biology News:First trimester smoking linked to oral clefts 2More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 2More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 3More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 4High blood sugar's impact on immune system holds clues to improving islet cell transplants 2High blood sugar's impact on immune system holds clues to improving islet cell transplants 3
FIA-series XYZ autosampler from Ocean Optics
Mouse Matrilin-4 from R&D Systems
EDTA Solution (pH 8.0) (0.5 M) from BioVision
...eals labware. Waterproof, moisture-proof film prev...nhydrous materials. Can be folded repeatedly and t...etched lengthwise at 21C (70F), wrapping film incr...ved, film only partially returns to original lengt...
Biology Products: